Standard Seed

What Standard Seed does

Standard Seed Corporation is a Delaware C-Corp founded in 2024, headquartered in Smyrna, USA, that operates an AI-powered biotech platform aimed at accelerating botanical drug discovery and natural medicine development. The company's core offering, the Botanical AI Factory™, structures work into three stages — Discovery (AI compound characterization including protein networks, molecular docking, mechanism of action, and target identification), Development (formulation, dosage, preclinical design, and IP positioning), and Regulatory (NDI, OTC, IND-enabling, and full IND pathway navigation). The platform bundles proprietary AI modules — Fusion Neural Network, Human Protein Network, Mass Spec AI, Virtual Forest, Clinical Trials Module, and a conversational interface called Mother Nature Chat — along with NCI-60 cell line screening integration.

The company monetizes through a tiered membership model: free Academic and Nonprofit tiers, an Associate tier at $500/year, a Community tier at $1,000/year, and a Community+AI tier at $10,000/year that includes the flagship Human Protein Network module, with add-on modules priced at $1,000/year each. Enterprise customers access a Regulatory Accelerator Program with milestone-based pricing tied to commercialization phases and risk profile, and Standard Seed also receives a 1.0% royalty on Net Sales per patent category (capped at 5.0% total) where it materially contributes to patents. Customer segments span pharmaceutical and biotech companies, botanical product manufacturers, academic institutions, mission-driven nonprofits, and independent researchers.

Standard Seed operates a global collaborative network of more than 20 partners including verified labs, manufacturers, and academic institutions such as Cambridge Crystallography Data Centre, Chemical.ai, the Network of Applied Pharmacognosy, and the University of Peradeniya. The company has built credibility through a peer-reviewed publication in Computers in Biology and Medicine (June 2025) on de novo drug design using MPNN and LSTM-based transfer learning, and through presentations at Cannabizcon 2026 and CannMed 2026, including a joint oncology flavonoid research collaboration with AULV. With 1-10 employees and a single $100,000 seed round from Elmsted Partners LLC closed in February 2026, the company remains at a very early operational stage.

Name

Standard Seed

Legal name

Standard Seed Corporation

Website

https://standardseedai.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Standard Seed Corporation operates an AI-powered biotech platform that accelerates botanical drug discovery through compound characterization, target identification, and FDA regulatory pathway navigation, serving pharmaceutical companies, manufacturers, and academic researchers via tiered memberships and a milestone-based regulatory accelerator program.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Trait Discovery & Functional Genomics (Target ID/Validation) (AFABALAC)

akta.pro secondary industry

Digital Breeding & Bioinformatics Software (Breeding informatics, decision tools) (AFABALAL)

Keywords

• AI drug discovery
• Botanical compound analysis
• Regulatory accelerator services
• Molecular docking software
• Clinical trial pathway

Headquarters

HQ city

Smyrna

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Membership Subscriptions: Tiered membership subscriptions from free academic/nonprofit tiers to paid community memberships at $1,000/year and premium AI-enabled memberships at $10,000/year.
2. AI Module Licensing: AI licensing bundled with memberships. Core Human Protein Network module included, additional modules at $1,000/year each (Mass Spec AI, Fusion Neural Network, Virtual Forest, Clinical Trials Module, Mother Nature Chat).
3. Regulatory Accelerator Program: Milestone-based pricing for products moving into regulated medical markets. Scientific analysis, regulatory dossier support, and clinical trial pathways with pricing tied to commercialization phases and risk profile.
4. Royalty Revenue Sharing: Where Standard Seed materially contributes to covered patent categories, they receive 1.0% of Net Sales per category, capped at 5.0% total. No double recovery. Mutual data governance.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Standard Seed operates an AI-powered biotech platform for botanical compound characterization and drug discovery. Its Botanical AI Factory™ platform uses proprietary AI (Fusion Neural Network, Human Protein Network) to analyze plant-based compounds, identify therapeutic targets via protein networks, molecular docking, and mechanism-of-action prediction. The company pairs this with a Regulatory Accelerator Program that guides botanical products through FDA pathways (NDI, OTC, IND-enabling, full IND) and university-facilitated clinical trials under milestone-based pricing.

Product overview

Standard Seed operates as a modular AI-powered biotech platform for botanical and pharmaceutical research. The core offering is the Botanical AI Factory™ platform, supplemented by individual AI modules (Human Protein Network, Mass Spec AI, Fusion Neural Network, Virtual Forest, Clinical Trials Module, Mother Nature Chat) that can be licensed additively. The platform follows a three-stage pipeline: Discovery (AI compound analysis), Development (formulation and regulatory strategy), and Regulatory (FDA pathway navigation). Enterprise clients can access the Regulatory Accelerator Program for medical market commercialization. The company also offers membership tiers (Academic, Nonprofit, Community, Community + AI, Associate) providing research library access, education curriculum, and collaborative research pathways.

Differentiator

Problem solved

Functional benefit

Brands

• Botanical AI Factory: AI platform for characterizing compounds and botanicals with protein networks, docking, mechanism of action, and target identification.
• Fusion Neural Network
• Human Protein Network

Products and services

• Botanical AI Factory™
• Regulatory Accelerator Program
• Standard Seed Corporation Seal

Quantifiable outcome

• 1% royalty per patent category with 5% total cap when Standard Seed materially contributes
• +1 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature9 records

Partnerships

Six partnerships are on record, tiered core and minor.

• AULVcoreStrategic or Co-development Partner · 1 January 2026Strategic partnership for joint research on botanical flavonoids in oncology therapeutics. Collaboration included presentation at Cannabizcon 2026 exploring how botanical flavonoids can be evaluated, optimized, and translated into oncology treatments using Standard Seed's AI discovery platform.
• Cambridge Crystallography Data CentrecoreTechnology or IntegrationAcademic partner providing crystallographic data and structural analysis capabilities for botanical compound characterization in drug discovery.
• Chemical.aicoreTechnology or IntegrationLaboratory partner providing chemical analysis and AI-powered compound characterization services for botanical research.
• Network of Applied PharmacognosycoreStrategic or Co-development PartnerAcademic network partner providing specialized pharmacognosy expertise and collaborative research opportunities in botanical science.
• University of PeradeniyacoreStrategic or Co-development PartnerAcademic institution partner providing research collaboration and educational expertise in botanical sciences.
• Venustas LawminorImplementation/ SI/ Consulting PartnerLegal partner providing regulatory and compliance expertise for botanical product development and FDA submissions.

Scale indicators3 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to accelerate pharmaceutical R&D. Directly comparable to Standard Seed's AI-powered drug discovery approach, though operating at far greater scale across multiple therapeutic areas beyond botanical.
• Atomwise: AI-driven small molecule drug discovery company using structure-based deep learning. Directly comparable on the AI-driven compound characterization and target identification axis, though focused on synthetic chemistry rather than botanical compounds.
• Benevolent AI: AI-driven drug discovery company combining knowledge graphs and machine learning to identify novel therapeutic targets. Comparable on the knowledge graph + ML + target identification architecture, which mirrors Standard Seed's Human Protein Network and Fusion Neural Network modules.
• Recursion Pharmaceuticals: Clinical-stage AI biotech using machine learning and high-throughput experimentation for drug discovery across multiple indications. Comparable as an AI-first drug discovery platform, though with broader therapeutic scope and significantly more capital than Standard Seed's botanical focus.
• Schrödinger: Computational chemistry and molecular simulation platform for drug discovery and materials science. Closely comparable to Standard Seed's molecular docking, mechanism-of-action, and target identification capabilities within the Botanical AI Factory, with an established enterprise software plus co-developed therapeutics business.
• Exscientia: AI-native pharmatech company using generative AI and automation to design and develop new medicines. Comparable AI-first drug discovery business model with pharma partnerships, though at far greater scale and capital than Standard Seed.
• XtalPi: AI-driven drug discovery company combining computational chemistry, quantum physics, and machine learning for molecular design. Comparable AI-first pharma platform with predictive modeling and molecular docking capabilities overlapping with Standard Seed's platform.

Broad incumbents

• Ginkgo Bioworks: Synthetic biology platform using automated organism engineering for applications across pharma, agriculture, and industrial biotech. Broad incumbent in the AI/synbio space with comparable scientific infrastructure but focused on organism engineering rather than botanical drug discovery.

Emerging players

• Cyclica: AI-driven polypharmacology platform for drug discovery with proteome-wide target identification. Comparable on AI-enabled target identification for small molecules, though with different therapeutic scope than Standard Seed's botanical specialization.
• Cannabis Biosciences: Emerging biotech focused on botanical/cannabis-derived pharmaceutical development with AI-enabled discovery. Closest emerging peer to Standard Seed's cannabis-adjacent botanical pharma focus, including FDA pathway navigation and clinical development of plant-derived therapeutics.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sulimansharif

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Standard Seed